Provided by Tiger Fintech (Singapore) Pte. Ltd.

Recursion Pharmaceuticals, Inc.

5.62
+0.20503.79%
Volume:9.76M
Turnover:54.60M
Market Cap:2.26B
PE:-3.32
High:5.70
Open:5.50
Low:5.46
Close:5.41
Loading ...

Analysts Offer Insights on Healthcare Companies: Ramsay Health Care (OtherRMSYF) and Recursion Pharmaceuticals (RXRX)

TIPRANKS
·
05 Mar

Why Recursion Pharmaceuticals, Inc. (RXRX) Crashed on Monday

Insider Monkey
·
05 Mar

Recursion Pharmaceuticals Inc (RXRX) Q4 2024 Earnings Call Highlights: Strong Financial ...

GuruFocus.com
·
04 Mar

Recursion Pharmaceuticals (NasdaqGS:RXRX) Surges 6% Following US$500 Million Follow-On Equity Offering

Simply Wall St.
·
04 Mar

Stock Track | Recursion Pharmaceuticals Plunges 5.06% on Wider-Than-Expected Q4 Loss

Stock Track
·
03 Mar

Company News for Mar 3, 2025

Zacks
·
03 Mar

Recursion Pharmaceuticals Full Year 2024 Earnings: Misses Expectations

Simply Wall St.
·
01 Mar

Recursion Pharmaceuticals Reports Mixed 2024 Financial Results

TIPRANKS
·
01 Mar

Cathie Wood’s ARK Investment buys 653K shares of Recursion Pharmaceuticals today

TIPRANKS
·
01 Mar

Strong Buy Recommendation for Recursion Pharmaceuticals: Leading Techbio Innovator with Robust Financials and Strategic AI Integration

TIPRANKS
·
01 Mar

Recursion Pharmaceuticals (RXRX) Gets a Hold from TD Cowen

TIPRANKS
·
01 Mar

Recursion Pharmaceuticals price target lowered to $6 from $7 at Leerink

TIPRANKS
·
01 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Recursion Pharmaceuticals, DoubleVerify Holdings, Praxis Precision Medicines

Reuters
·
28 Feb

Recursion Pharma Shares Drop After Wider-Than-Expected 4Q Loss

Dow Jones
·
28 Feb

BUZZ-Nvidia-backed Recursion Pharmaceuticals falls on bigger-than-expected Q4 loss

Reuters
·
28 Feb

Recursion Pharmaceuticals Shares Slide 10% After Bigger-Than-Expected Q4 Loss

THOMSON REUTERS
·
28 Feb

Recursion Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

Recursion Pharmaceuticals Shares Slide 12.3% Premarket After Bigger-Than-Expected Q4 Loss

THOMSON REUTERS
·
28 Feb

Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
28 Feb

Recursion Pharmaceuticals: Files for Offering of up to $500 Mln Class a Common Stock - SEC Filing

THOMSON REUTERS
·
28 Feb